1. Medtech Insight
  2. >>Business
  4. >>Clinical Trials

Abiomed Launches Plan To Counter Unfavorable Impella Data

 
• By Reed Miller

Abiomed is trying to counter the negative publicity created by the recent publication of retrospective studies showing higher costs and worse outcomes in coronary intervention cases with Impella than in comparable procedures with intra-aortic balloon pumps. The company insists this analysis is deeply flawed.

Abiomed’s Impella 5.0 Heart Pump Transcatheter Circulatory Support Device
Abiomed Impella 5.0 Heart Pump Percutaneous Circulatory Support Device • Source: Abiomed Inc.

[Editor's note: This article was updated on 14 February 2020 to clarify that Abiomed has invested more than $100m over the past five years in clinical research on the Impella heart pump platform. Abiomed has not committed to spend another $100m on new physician education and communication programs.]

Abiomed Inc. has launched physician education and communication programs to support its Impella line of heart pumps against negative publicity caused by unfavorable registry studies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D